Eli Lilly Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly

LLY 1,075

+0.4%

3:43 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mel Spivak who wrote (267)	7/17/1998 4:34:00 PM
From: Maxer	Read Replies (1) of 642

Mel-- interesting, but doubt this is it. From Motley Fool. Inhale Therapeutic Systems (Nasdaq: INHL) picked up $3 1/2 to $31 1/4 a day after saying Phase IIb trials of its inhaled powder-form of insulin resulted in blood glucose control levels comparable to traditional insulin injections. The firm added that the 121 patient trial group "significantly favored" inhaling insulin instead of receiving injections. Eli Lilly & Co. (NYSE: LLY) and Denmark's Novo-Nordisk (NYSE: NVO), which is also working on inhalable insulin with drug delivery systems developer Aradigm Corp. (Nasdaq: ARDM), currently dominate the $3 billion to $4 billion worldwide insulin market. Inhale Therapeutics said it will conduct more trials of the product with marketing partner Pfizer (NYSE: PFE) in November. Diabetics interested in participating in the trials can receive more information by calling (800) 438-1985.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next